Anacor Announces Second Development Candidate in Animal Health Under Research Collaboration With Eli Lilly and Company

  Anacor Announces Second Development Candidate in Animal Health Under
  Research Collaboration With Eli Lilly and Company

Business Wire

PALO ALTO, Calif. -- December 04, 2012

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has achieved its
second development candidate in its animal health collaboration with Eli Lilly
and Company (Lilly). Anacor’s research collaboration with Lilly is focused on
the use of Anacor’s boron chemistry to discover products for a variety of
animal health applications. Under the terms of the collaboration, Anacor will
receive a $1 million payment for achieving this milestone. Anacor and Lilly
achieved the first development candidate under this collaboration in August
2011.

“Our collaboration with Lilly has proven to be very productive, resulting in
two animal health development candidates in just over two years,” said David
Perry, Chief Executive Officer of Anacor Pharmaceuticals. “Both of these
product candidates are focused on large market opportunities that could result
in a significant economic return for Anacor if these therapies are approved.”

Pursuant to the terms of the agreement, Lilly has funded the research that
resulted in this compound and will be responsible for future development and
commercialization. Anacor is eligible to receive additional development and
regulatory milestones as well as tiered royalties from the high single digits
to low double digits on future sales.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — tavaborole, a topical antifungal for the treatment of
onychomycosis, and AN2728, a topical anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other clinical product candidates —
AN2718 and AN2898, which are backup compounds to tavaborole and AN2728,
respectively, and AN3365 (formerly known as GSK2251052, or GSK‘052), a
systemic antibiotic for the treatment of infections caused by Gram-negative
bacteria, which previously was licensed to GlaxoSmithKlineLLC, or GSK. GSK
will be returning all rights to the compound to us and we are considering our
options for further development, if any, of this compound. We have discovered
three other compounds that we have out-licensed for further development — two
compounds for the treatment of animal health indications that are licensed to
Eli Lilly and Company, or Lilly, and AN5568, also referred to as SCYX-7158,
for human African trypanosomiasis (HAT, or sleeping sickness), which is
licensed to Drugs for Neglected Diseases initiative, or DNDi. We also have a
pipeline of other internally discovered topical and systemic boron-based
compounds in development. For more information, visit http://www.anacor.com.

Forward-Looking Statements

This press release contains forward-looking statements that relate to future
events including the development and commercialization of a compound in animal
health and our collaboration with Lilly. These forward looking statements
involve known and unknown risks, uncertainties and other factors that could
cause timing, actual levels of activity, performance or achievement to differ
materially from those expressed or implied by these forward-looking
statements, including risks related to enrollment and successful completion of
our trials, risk of unforeseen side effects and risks related to regulatory
approval of new drug candidates. These statements reflect the views of Anacor
as of the date of this press release with respect to future events and, except
as required by law, it undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new information, future
events or otherwise after the date of this press release.

Contact:

Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
dsheel@anacor.com
 
Press spacebar to pause and continue. Press esc to stop.